Archer produces graphene inks
Archer Exploration (ASX:AXE) has provided results from its collaboration with The University of Adelaide.
The company has informed the market that graphene inks were prepared using a combination of established, publically available and proprietary methods – which took advantage of its chemically superior Campoona graphite.
It’s worth noting that remains a speculative play and investors should seek professional financial advice if considering this company for their portfolio.
Two printing techniques were undertaken during the trial, which utilised an inkjet printer and a laser-scribed printer for the preparation of basic electrode patterns (below).
AXE has noted that the electrochemical characteristics of the printed electrodes were obtained, and are adequate for biosensor application use.
The properties of the inks have yet to be thoroughly tested or optimised, and will be the subject of the ongoing collaboration.
The University of Adelaide verified the authenticity of the graphene materials, properties and quality via technical analysis. This analysis included cyclic voltametric experiments that confirmed the capability of the printed electrodes to be used in electrochemical biosensor applications.
In addition, the technical analysis confirmed that graphite sourced from AXE’s Campoona deposit could be used to produce graphene-based inks and printed electrodes in-line with or better than benchmarks set in related research fields.
Both parties will now prioritise securing intellectual property rights to commercially available technology in relation to the inks.
AXE CEO Dr Mohammad Choucair spoke on the announcement, “The work with The University of Adelaide Graphene Hub highlights our continue and successful collaborative efforts in executing our advanced materials and technology strategy, and provides Archer with commercial opportunities to develop high-end graphene products and technologies in the focus area of human health, to underpin further development of our Campoona graphite resource.”
Graphene inks and printed graphene electronic device products form part of the emerging US$2 billion conductive ink technology market.
This market is set to service niche segments of the global biosensor space, which is expected to grow to US$27 billion by 2022.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.